Lamivudina Aurovitas (Lamivudine)

Lamivudine is a nucleoside analogue that, after cellular phosphorylation, becomes an active triphosphate. This active form competes with natural nucleotides for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and preventing the virus from replicating its genome.

The specific dose of lamivudine is determined by the prescribing clinician based on the patient’s condition, age, weight, renal function and other factors. Healthcare providers follow established guidelines and adjust the regimen as needed for optimal therapeutic effect.

The safety of lamivudine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient oral administration. Compared with some older NRTIs, it has lower mitochondrial toxicity and is often combined with other agents to form highly effective combination regimens for HIV and hepatitis B.

Lamivudina Aurovitas should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposure to extreme temperatures.

Lamivudina Aurovitas is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water and the dosing schedule is based on the individual treatment plan.

Serious adverse events, although rare, can include lactic acidosis, severe hepatotoxicity, and pancreatitis. Patients should be monitored for signs such as unexplained fatigue, abdominal pain, jaundice or rapid weight loss, and seek immediate medical attention if these occur.

Lamivudina Aurovitas is contraindicated in individuals with known hypersensitivity to lamivudine or any of the tablet’s excipients. Patients with severe renal impairment may require dose adjustment, and those with active liver disease should be closely monitored by their healthcare provider.